New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Portfolio Pulse from
Bristol Myers Squibb (BMY) released new five-year data for Sotyktu (deucravacitinib), showing consistent safety and durable response rates in treating moderate-to-severe plaque psoriasis.
February 16, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's Sotyktu demonstrates consistent safety and durable response rates over five years for plaque psoriasis, potentially boosting investor confidence.
The positive long-term data for Sotyktu could enhance Bristol Myers Squibb's market position in treating plaque psoriasis, likely leading to increased investor confidence and a potential short-term stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100